|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||582.00 - 617.70|
|52-week range||147.20 - 617.70|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||8.88|
|Forward dividend & yield||N/A (N/A)|
|1y target est||450.00|
Britain is on amber alert. The country faces the prospect of a shortage of everyday medications, from painkillers and steroids to anaesthetics. While one third of generic medicines used by the NHS are manufactured in Britain, the same proportion comes from India. The Covid crisis unfolding on the subcontinent has drastically reduced factory output. The volume of medication being shipped to the UK is dropping and stocks could reach dangerously low levels in the coming months, the trade body representing generic drug makers in the UK has warned. The British Generic Manufacturers Association (BGMA) says around two thirds of its members have suffered disruption to supplies. Of those, nearly three quarters say the impact could be felt in the next three months. These drug makers are already stretched thanks to the pandemic so the supply chain squeeze from India poses a real threat, Mark Samuels, the BGMA’s chief executive, says. “They are now on amber alert because of India’s terrible crisis. This situation is a risk to the NHS. Our manufacturers and others in Europe will try to mitigate any disruption, but we are worried.”
New Delhi, May 27 (PTI) Shares of drug firm Wockhardt on Thursday tumbled nearly 15 per cent after the company reported a consolidated net loss of Rs 106.84 crore for the quarter ended March 31, 2021.
New Delhi, May 27 (PTI) Drug firm Wockhardt on Thursday reported a consolidated net loss of Rs 106.84 crore for the quarter ended March 31, 2021.